Cargando…

Landscape of circulating tumour DNA in metastatic breast cancer

BACKGROUND: We describe the genomic landscape of circulating tumour DNA (ctDNA) across pathological subtypes of metastatic breast cancer. METHODS: 255 clinically annotated patients with ctDNA testing by Guardant360 were stratified into HR+, HER2+, and TNBC cohorts. Frequency and heterogeneity of alt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Davis, Andrew A., Jacob, Saya, Gerratana, Lorenzo, Shah, Ami N., Wehbe, Firas, Katam, Neelima, Zhang, Qiang, Flaum, Lisa, Siziopikou, Kalliopi P., Platanias, Leonidas C., Gradishar, William J., Behdad, Amir, Cristofanilli, Massimo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Research paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7381501/ https://www.ncbi.nlm.nih.gov/pubmed/32707446 http://dx.doi.org/10.1016/j.ebiom.2020.102914

Ejemplares similares

Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer
por: Davis, Andrew A., et al.
Publicado: (2019)

Positive predictive value of ERBB2 copy number gain by tissue or circulating tumor DNA next-generation sequencing across advanced cancers
por: Shah, Ami N., et al.
Publicado: (2022)

Longitudinal Dynamics of Circulating Tumor Cells and Circulating Tumor DNA for Treatment Monitoring in Metastatic Breast Cancer
por: Gerratana, Lorenzo, et al.
Publicado: (2021)

Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis
por: Gerratana, Lorenzo, et al.
Publicado: (2023)

Cell-free DNA comparative analysis of the genomic landscape of first-line hormone receptor-positive metastatic breast cancer from the US and China
por: Liu, Xiaoran, et al.
Publicado: (2021)

Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancer
por: Davis, Andrew A., et al.
Publicado: (2022)

Outcomes of Cancer Patients with COVID-19 in a Hospital System in the Chicago Metropolitan Area
por: Mina, Alain, et al.
Publicado: (2022)

Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer
por: Shah, Ami N, et al.
Publicado: (2020)

Dynamic Glycoprotein Hyposialylation Promotes Chemotherapy Evasion and Metastatic Seeding of Quiescent Circulating Tumor Cell Clusters in Breast Cancer
por: Dashzeveg, Nurmaa K., et al.
Publicado: (2023)

A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer
por: Santa-Maria, Cesar August, et al.
Publicado: (2018)

Single-Cells Isolation and Molecular Analysis: Focus on HER2-Low CTCs in Metastatic Breast Cancer
por: D’Amico, Paolo, et al.
Publicado: (2021)

Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA
por: Chae, Young Kwang, et al.
Publicado: (2016)

Circulating tumour cells in the -omics era: how far are we from achieving the ‘singularity’?
por: Visal, Tanvi H., et al.
Publicado: (2022)

Antineoplastic effects of selective CDK9 inhibition with atuveciclib on cancer stem-like cells in triple-negative breast cancer
por: Brisard, Daphne, et al.
Publicado: (2018)

The Landscape of Targeted Therapies in TNBC
por: Vagia, Elena, et al.
Publicado: (2020)

Circulating tumour cells are associated with increased risk of venous thromboembolism in metastatic breast cancer patients
por: Mego, M, et al.
Publicado: (2009)

Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation
por: Gerratana, Lorenzo, et al.
Publicado: (2022)

Circulating tumor cells in breast cancer: A tool whose time has come of age
por: Swaby, Ramona F, et al.
Publicado: (2011)

Genomic landscape of DNA repair genes in cancer
por: Chae, Young Kwang, et al.
Publicado: (2016)

Circulating Tumor Cell Clusters Are Frequently Detected in Women with Early-Stage Breast Cancer
por: Reduzzi, Carolina, et al.
Publicado: (2021)

AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications
por: Vakana, Eliza, et al.
Publicado: (2011)

ULK1 in type I interferon response
por: Saleiro, Diana, et al.
Publicado: (2015)

MNK Proteins as Therapeutic Targets in Leukemia
por: Mazewski, Candice, et al.
Publicado: (2023)

A novel approach to overcome drug resistance in acute myeloid leukemia
por: Mazewski, Candice, et al.
Publicado: (2023)

Emerging Role of Glioma Stem Cells in Mechanisms of Therapy Resistance
por: Eckerdt, Frank, et al.
Publicado: (2023)

Beta 2-Adrenergic Receptor in Circulating Cancer-Associated Cells Predicts for Increases in Stromal Macrophages in Circulation and Patient Survival in Metastatic Breast Cancer
por: Gardner, Kirby P., et al.
Publicado: (2022)

Advancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone
por: Cristofanilli, Massimo
Publicado: (2012)

Circulating tumor cells and novel biomarkers for prognostic and biological of breast cancer
por: Cristofanilli, M
Publicado: (2005)

Dynamic changes of live/apoptotic circulating tumour cells as predictive marker of response to Sunitinib in metastatic renal cancer
por: Rossi, E, et al.
Publicado: (2012)

Epithelial ovarian cancer risk: A review of the current genetic landscape
por: Flaum, Nicola, et al.
Publicado: (2019)

Gene essentiality landscape and druggable oncogenic dependencies in herpesviral primary effusion lymphoma
por: Manzano, Mark, et al.
Publicado: (2018)

Hormone Receptor–Positive/Human Epidermal Growth Receptor 2–Negative Metastatic Breast Cancer in Young Women: Emerging Data in the Era of Molecularly Targeted Agents
por: Shah, Ami N., et al.
Publicado: (2020)

Deregulation of Interferon Signaling in Malignant Cells
por: Katsoulidis, Efstratios, et al.
Publicado: (2010)

Innate Immune Mechanisms and Immunotherapy of Myeloid Malignancies
por: Small, Sara, et al.
Publicado: (2021)

Role of Biomarkers in the Management of Acute Myeloid Leukemia
por: Small, Sara, et al.
Publicado: (2022)

Detection and Characterization of Circulating Tumor Associated Cells in Metastatic Breast Cancer
por: Mu, Zhaomei, et al.
Publicado: (2016)

A novel small-molecule antagonizes PRMT5-mediated KLF4 methylation for targeted therapy
por: Zhou, Zhuan, et al.
Publicado: (2019)

Developmental therapeutics for inflammatory breast cancer: Biology and translational directions
por: Costa, Ricardo, et al.
Publicado: (2016)

TP53 mutations detected in circulating tumor cells present in the blood of metastatic triple negative breast cancer patients
por: Fernandez, Sandra V, et al.
Publicado: (2014)

Circulating tumour DNA in the evolving treatment landscape of locally advanced rectal cancer: where does it fit in?
por: Piercey, Oliver, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vm1pfnjovh9asf2hf8siet0nuo